Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

Don D. Sin; Bruce E. Miller; Annelyse Duvoix; S. F.Paul Man; Xuekui Zhang; Edwin K. Silverman; John E. Connett; Nicholas A. Anthonisen; Robert A. Wise; Donald Tashkin; Bartolome R. Celli; Lisa D. Edwards; Nicholas Locantore; William MacNee; Ruth Tal-Singer; David A. Lomas

doi:10.1164/rccm.201008-1220OC

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

Don D. Sin, Bruce E. Miller, Annelyse Duvoix, S. F.Paul Man, Xuekui Zhang, Edwin K. Silverman, John E. Connett, Nicholas A. Anthonisen, Robert A. Wise, Donald Tashkin, Bartolome R. Celli, Lisa D. Edwards, Nicholas Locantore, William MacNee, Ruth Tal-Singer, David A. Lomas

Biostatistics

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Abstract

Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects withCOPDthan in smokers or lifetimenonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD. Clinical trial registered with www.clinicaltrials.gov (NCT 00292552).

Original language	English (US)
Pages (from-to)	1187-1192
Number of pages	6
Journal	American journal of respiratory and critical care medicine
Volume	183
Issue number	9
DOIs	https://doi.org/10.1164/rccm.201008-1220OC
State	Published - May 1 2011

Keywords

Biomarker
Chemokine
Chronic obstructive pulmonary disease
PARC/CCL-18

Publisher link

10.1164/rccm.201008-1220OC

Find It

Find It at U of M Libraries

Cite this

Sin, D. D., Miller, B. E., Duvoix, A., Man, S. F. P., Zhang, X., Silverman, E. K., Connett, J. E., Anthonisen, N. A., Wise, R. A., Tashkin, D., Celli, B. R., Edwards, L. D., Locantore, N., MacNee, W., Tal-Singer, R., & Lomas, D. A. (2011). Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 183(9), 1187-1192. https://doi.org/10.1164/rccm.201008-1220OC

Sin, DD, Miller, BE, Duvoix, A, Man, SFP, Zhang, X, Silverman, EK, Connett, JE, Anthonisen, NA, Wise, RA, Tashkin, D, Celli, BR, Edwards, LD, Locantore, N, MacNee, W, Tal-Singer, R & Lomas, DA 2011, 'Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease', American journal of respiratory and critical care medicine, vol. 183, no. 9, pp. 1187-1192. https://doi.org/10.1164/rccm.201008-1220OC

@article{f80d0b7169464022b0577a2cae5b5cfa,

title = "Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease",

abstract = "Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects withCOPDthan in smokers or lifetimenonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD. Clinical trial registered with www.clinicaltrials.gov (NCT 00292552).",

keywords = "Biomarker, Chemokine, Chronic obstructive pulmonary disease, PARC/CCL-18",

author = "Sin, {Don D.} and Miller, {Bruce E.} and Annelyse Duvoix and Man, {S. F.Paul} and Xuekui Zhang and Silverman, {Edwin K.} and Connett, {John E.} and Anthonisen, {Nicholas A.} and Wise, {Robert A.} and Donald Tashkin and Celli, {Bartolome R.} and Edwards, {Lisa D.} and Nicholas Locantore and William MacNee and Ruth Tal-Singer and Lomas, {David A.}",

year = "2011",

month = may,

day = "1",

doi = "10.1164/rccm.201008-1220OC",

language = "English (US)",

volume = "183",

pages = "1187--1192",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "9",

}

TY - JOUR

T1 - Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

AU - Sin, Don D.

AU - Miller, Bruce E.

AU - Duvoix, Annelyse

AU - Man, S. F.Paul

AU - Zhang, Xuekui

AU - Silverman, Edwin K.

AU - Connett, John E.

AU - Anthonisen, Nicholas A.

AU - Wise, Robert A.

AU - Tashkin, Donald

AU - Celli, Bartolome R.

AU - Edwards, Lisa D.

AU - Locantore, Nicholas

AU - MacNee, William

AU - Tal-Singer, Ruth

AU - Lomas, David A.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects withCOPDthan in smokers or lifetimenonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD. Clinical trial registered with www.clinicaltrials.gov (NCT 00292552).

AB - Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects withCOPDthan in smokers or lifetimenonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD. Clinical trial registered with www.clinicaltrials.gov (NCT 00292552).

KW - Biomarker

KW - Chemokine

KW - Chronic obstructive pulmonary disease

KW - PARC/CCL-18

UR - http://www.scopus.com/inward/record.url?scp=79955513658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955513658&partnerID=8YFLogxK

U2 - 10.1164/rccm.201008-1220OC

DO - 10.1164/rccm.201008-1220OC

M3 - Article

C2 - 21216880

AN - SCOPUS:79955513658

SN - 1073-449X

VL - 183

SP - 1187

EP - 1192

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 9

ER -

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this